海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerability of 12 months of once daily treatment with 1 mg of RO3300074 in patients with symptomatic emphysema secondary to alpha-1-antitrypsin deficiency
- symptomatic emphysema secondary to alpha-1-antitrypsin deficiency
- Denmark, Spain, United Kingdom
- 2004-10-21
Authorised
- Estudio de fase IV, multicéntrico, aleatorizado y doble ciego para comparar la seguridad y eficacia de 180 µg de Pegasys® más 1000 ó 1200 mg de Copegus® con la combinación actualmente aprobada de 180 µg de Pegasys® más 800 mg de Copegus® en pacientes con infección por el virus de la hepatitis C crónica del genotipo 1 coinfectados con el virus de la inmunodeficiencia humana (VIH-1), que no hayan sido previamente tratados con interferón.
- Pacientes con virus de la Hepatitis C crónica (HCC) del genotipo 1 coinfectados por virus de la inmunodeficiencia humana de tipo 1 (VIH-1).
- Portugal, Spain
- 2006-03-10
Authorised
- MK-3475 vs. Docetaxel in Second-Line Non-Small Cell Lung Cancer
- MedDRA version: 20.0 Level: LLT Classification code 10066490 Term: Progression of non-small cell lung cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan, United Kingdom, United States
- 2013-01-17
Authorised
- “Neo-Adjuvant Treatment with the CDK4,6 inhibitor Palbociclib in HER2-positive and ER-positive breast cancer: effect on Ki67 and apoptosis before, during and after treatment “
- Women with a diagnosis of invasive unilateral non metastatic HER2-positive and ER-positive breast cancer suitable for neoadjuvant therapy MedDRA version: 17.1 Level: LLT Classification code 10006283 Term: Breast neoplasm malignant female System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-10-28
Authorised
- CHemotherapy plus Enzalutamide In first line therapy for castration Resistant prOstate caNcer
- castration Resistant prOstate caNcer;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-06-20
Authorised
- Study Evaluating the safety and effectiveness of EVICEL® used for Suture-line sealing to provide a watertight closure during Paediatric Neurosurgical Procedures
- Subjects undergoing neurosurgical cranial procedures, requiring water-tight closures (suture-line sealing) in dura-mater during the surgery;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
- United Kingdom
- 2014-05-23
Authorised
- Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI
- Unresectable and metastatic colorectal cancer MedDRA version: 16.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-02-04
Authorised
- Clinical effect of antithrombin concentrate treatment on uterine blood flow and the amount of Atenativ needed to maintain a normal antithrombin level during two weeks in early and severe preeclampsia
- Early and severe preeclampsia with low antithrombin activity.;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
- Sweden
- 2012-12-27
Authorised
- A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment
- gastro-intestinal stromal tumour MedDRA version: 9.1 Level: LLT Classification code 10051066 Term: Gastrointestinal stromal tumour
- Austria, Belgium, France, Germany, Hungary, Netherlands, Spain, United Kingdom
- 2008-07-16
Authorised
- Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma - The NACHO trial
- unresecable, metastatic or recurrent cholangiocarcinoma (intrahepatic cholangiocellular carcinoma, bile duct cancer, gall bladder carcinoma) MedDRA version: 18.1 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Germany
- 2015-12-17